Discounted Cash Flow
Madrigal Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $48.3k | $-26.4m | $-17.6m | -54629.9% | $-5.07 |
| 2017 | $558.0k (1055.2%) | $-31.2m (-18.1%) | $-22.4m (-27.4%) | -5583.2% (89.8%) | $-2.54 (49.9%) |
| 2018 | $7.7m (1274.7%) | $-32.8m (-5.3%) | $-25.5m (-13.8%) | -427.7% (92.3%) | $-2.22 (12.6%) |
| 2019 | $0 (-100.0%) | $-83.9m (-155.9%) | $-41.8m (-63.7%) | — | $-5.45 (-145.5%) |
| 2020 | $0 | $-202.2m (-140.9%) | $-157.9m (-277.8%) | — | $-13.09 (-140.2%) |
| 2021 | $0 | $-241.8m (-19.6%) | $-184.1m (-16.6%) | — | $-14.63 (-11.8%) |
| 2022 | $0 | $-295.4m (-22.1%) | $-225.1m (-22.2%) | — | $-17.23 (-17.8%) |
| 2023 | $0 | $-373.6m (-26.5%) | $-325.7m (-44.7%) | — | $-19.99 (-16.0%) |
| 2024 | $180.1m | $-465.9m (-24.7%) | $-457.0m (-40.3%) | -258.6% | $-21.90 (-9.6%) |
| 2025 | $958.4m (432.1%) | $-288.3m (38.1%) | $-190.0m (58.4%) | -30.1% (88.4%) | $-12.85 (41.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.